Trials in South Dakota.
8 APOE4-relevant Alzheimer’s trials run in South Dakota — 1 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Non-carriers only, not for APOE4NCT00574132Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…
- Drug trial for diagnosed APOE4 carriersNCT00575055Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…
- Studies APOE4, but only in diagnosed patientsNCT01329536The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease
This study looks at whether the APOE4 gene variant is more common in people with late-onset Alzheimer's who show agitation than in those who do not.…
- Cancer trial, not for healthy carriersNCT01227954Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
This trial tests whether a more precise form of whole-brain radiation can spare the hippocampus, the brain's memory center, in people whose cancer has spread…
- Genetic study, not APOE4-specificNCT01329523A Study to Compare Genetic Variations of IGF-I and IGF-II
This study looks at whether small differences in the genes for insulin-like growth factors, called IGF-I and IGF-II, are linked to dementia, especially…
- Rare disease registry, not APOE4-relevantNCT01793168Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
This is not a drug or treatment trial. It is a free patient registry run by Sanford Research in South Dakota. People with a rare disease, an undiagnosed…
- Drug trial, genotype not specified, ARIA riskNCT05026866A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
This trial tests donanemab, an anti-amyloid antibody given by infusion, against a placebo in people with no memory or thinking problems but signs of amyloid in…
- Early Alzheimer's drug trial, not 4-specificNCT05531526Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
This trial tests whether a pill called AR1001 can slow memory and thinking decline in people with early Alzheimer's, compared with a placebo. It also checks…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.